Five years of COPD primary care: Patterns of management of high-risk COPD and opportunities for optimising care in Australia 2015-2019 (COPD Opportunity Analysis in Australia)

Study identification

• EU PAS number:
  EUPAS49365
• Study ID:
  49527
• Official title and acronym:
  Five years of COPD primary care: Patterns of management of high-risk COPD and opportunities for optimising care in Australia 2015-2019 (COPD Opportunity Analysis in Australia)
• DARWIN EU® study:
  No
• Study countries:
  Australia
• Study description:
  The main aim for this “Opportunity Analysis” is to assess the management of patients with high-risk COPD over 5 years in Australian primary care and describe opportunities for treatment optimisation in line with the CONQUEST Quality Standards, over this period. The objectives per quality standards are: 1. Assess whether undiagnosed patients who potentially have high-risk COPD are actively and promptly identified in Australian primary care. 2. Assess whether high-risk patients with newly diagnosed COPD receive a proper assessment and quantification of future risk of exacerbations and cardiac events within 12 months of diagnosis. 3. Assess whether pharmaceutical and non-pharmacological therapy is provided to patients with high-risk COPD within 12 months of meeting criteria for high-risk COPD. 4. Assess whether high-risk patients diagnosed with COPD are followed up appropriately over a 12m period following baseline assessment
• Study status:
  Ongoing

Research institutions and networks

Institutions

Optimum Patient Care Australia

Australia

Study timelines

Date when funding contract was signed

Actual:29/06/2022

Study start date

Actual:01/08/2022

Date of final study report

Planned:31/12/2023

Sources of funding

Other

Pharmaceutical company and other private sector 

More details on funding

AstraZeneca, Optimum Patient Care Australia

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable